Stockreport

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Invivyd, Inc.  (IVVD) 
PDF Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal [Read more]